D. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Tevogen Bio Stock Performance

Shares of NASDAQ TVGN traded down $0.03 during mid-day trading on Tuesday, reaching $1.24. The company's stock had a trading volume of 556,484 shares, compared to its average volume of 5,051,353. Tevogen Bio has a 52 week low of $0.26 and a 52 week high of $3.09. The stock has a fifty day moving average of $1.14 and a two-hundred day moving average of $1.20.

Insiders Place Their Bets

In other news, CEO Ryan H. Saadi sold 1,438,206 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $1.23, for a total value of $1,768,993.38. Following the transaction, the chief executive officer now owns 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. The trade was a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 73.24% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tevogen Bio

Several institutional investors have recently bought and sold shares of TVGN. Geode Capital Management LLC boosted its holdings in shares of Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock valued at $465,000 after purchasing an additional 107,566 shares during the last quarter. Northern Trust Corp raised its stake in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after purchasing an additional 13,595 shares in the last quarter. Nuveen LLC purchased a new stake in Tevogen Bio during the first quarter valued at $97,000. XTX Topco Ltd purchased a new position in shares of Tevogen Bio in the 4th quarter worth $55,000. Finally, Barclays PLC increased its holdings in shares of Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after buying an additional 12,847 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.